Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Pugliatti, Maura, Hartung, Hans-Peter, Oreja-Guevara, Celia, Pozzilli, Carlo, Airas, Laura, Alkhawajah, Mona, Grigoriadis, Nikolaos, Magyari, Melinda, Van Wijmeersch, Bart, Zakaria, Magd, Linker, Ralf, Chan, Andrew, Vermersch, Patrick, Berger, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620960/
https://www.ncbi.nlm.nih.gov/pubmed/36325318
http://dx.doi.org/10.3389/fimmu.2022.1045101
_version_ 1784821434045956096
author Pugliatti, Maura
Hartung, Hans-Peter
Oreja-Guevara, Celia
Pozzilli, Carlo
Airas, Laura
Alkhawajah, Mona
Grigoriadis, Nikolaos
Magyari, Melinda
Van Wijmeersch, Bart
Zakaria, Magd
Linker, Ralf
Chan, Andrew
Vermersch, Patrick
Berger, Thomas
author_facet Pugliatti, Maura
Hartung, Hans-Peter
Oreja-Guevara, Celia
Pozzilli, Carlo
Airas, Laura
Alkhawajah, Mona
Grigoriadis, Nikolaos
Magyari, Melinda
Van Wijmeersch, Bart
Zakaria, Magd
Linker, Ralf
Chan, Andrew
Vermersch, Patrick
Berger, Thomas
author_sort Pugliatti, Maura
collection PubMed
description It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.
format Online
Article
Text
id pubmed-9620960
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96209602022-11-01 Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in Pugliatti, Maura Hartung, Hans-Peter Oreja-Guevara, Celia Pozzilli, Carlo Airas, Laura Alkhawajah, Mona Grigoriadis, Nikolaos Magyari, Melinda Van Wijmeersch, Bart Zakaria, Magd Linker, Ralf Chan, Andrew Vermersch, Patrick Berger, Thomas Front Immunol Immunology It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered. Frontiers Media S.A. 2022-10-17 /pmc/articles/PMC9620960/ /pubmed/36325318 http://dx.doi.org/10.3389/fimmu.2022.1045101 Text en Copyright © 2022 Pugliatti, Hartung, Oreja-Guevara, Pozzilli, Airas, Alkhawajah, Grigoriadis, Magyari, Van Wijmeersch, Zakaria, Linker, Chan, Vermersch and Berger https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Pugliatti, Maura
Hartung, Hans-Peter
Oreja-Guevara, Celia
Pozzilli, Carlo
Airas, Laura
Alkhawajah, Mona
Grigoriadis, Nikolaos
Magyari, Melinda
Van Wijmeersch, Bart
Zakaria, Magd
Linker, Ralf
Chan, Andrew
Vermersch, Patrick
Berger, Thomas
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
title Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
title_full Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
title_fullStr Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
title_full_unstemmed Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
title_short Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
title_sort anti-sars-cov-2 vaccination in people with multiple sclerosis: lessons learnt a year in
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620960/
https://www.ncbi.nlm.nih.gov/pubmed/36325318
http://dx.doi.org/10.3389/fimmu.2022.1045101
work_keys_str_mv AT pugliattimaura antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT hartunghanspeter antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT orejaguevaracelia antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT pozzillicarlo antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT airaslaura antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT alkhawajahmona antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT grigoriadisnikolaos antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT magyarimelinda antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT vanwijmeerschbart antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT zakariamagd antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT linkerralf antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT chanandrew antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT vermerschpatrick antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin
AT bergerthomas antisarscov2vaccinationinpeoplewithmultiplesclerosislessonslearntayearin

Ejemplares similares